COMP <GO>
ELMD vs LLY // FORWARD P/E MULTIPLE
Electromed Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ELMD 4
— LLY 9
▲ FORWARD P/E MULTIPLE LEADER: ELMD
LAST: $27.68 (+1.47%) • MKT CAP: $229.4M
forward-pe
25.5x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
forward-pe
30.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELMD VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELMD | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.10% | 83.64% | -5.54 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 24.10% | 32.36% | -8.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.8x | 36.4x | -14.62 | ELMD | /valuation <GO> |
| Free Cash Flow Yield | 4.85% | 2.30% | +2.55 | ELMD | /fcf-yield <GO> |
| Operating Margin | 15.10% | 40.21% | -25.11 | LLY | /operating-margins <GO> |
| Net Profit Margin | 11.80% | 31.90% | -20.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 17.00% | 45.51% | -28.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 17.64 | 9.29 | +8.35 | ELMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 66.6 | -17.80 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 25.5x | 30.6x | -5.12 | ELMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $229.4M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELMD REV | LLY REV | ELMD GROSS % | LLY GROSS % | ELMD FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $64.0M | $65.18B | 78.1% | 83.0% | $11.1M | $16.81B |
| FY 2024 | $54.7M | $45.04B | 76.3% | 81.3% | $8.8M | $8.82B |
| FY 2023 | $48.1M | $34.12B | — | 79.3% | $1.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELMD // BETA —
LLY // BETA 0.51